Business Context and Reporting Period
Daré Bioscience, Inc. filed this Form 8-K on April 11, 2019, to report the closing of a previously announced underwritten public offering of common stock. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
- Shares Issued: 4,575,000 shares of common stock.
- Public Offering Price: $1.10 per share.
- Net Proceeds: Approximately $4.47 million (after underwriting discounts, commissions, and offering expenses).
- Net Consideration Received: $0.98 per share.
Material Changes
The filing details a material change to the terms of outstanding warrants issued in February 2018. These warrants, covering up to 3,720,500 shares, contain price-based anti-dilution provisions. Because the net consideration received per share in this offering ($0.98) was below the previous warrant exercise price ($3.00), the exercise price was automatically reduced to $0.98 per share effective April 11, 2019.
Outlook and Risks
The filing does not provide specific forward-looking guidance, management commentary on future operations, or a discussion of risks beyond the mechanical impact of the anti-dilution provision on existing warrant holders. The primary event is the capital raise and the resulting adjustment to warrant terms.
Investor Verification Checklist
- Verify the total number of outstanding warrants (3,720,500) and their new exercise price ($0.98).
- Confirm the dilution impact of the 4,575,000 newly issued shares on existing shareholders.
- Review the company's cash position post-offering to assess runway for operations.
- Check for any other securities issued at prices below $0.98 that could trigger further warrant adjustments.